Treatment directed at TRPV1 significantly alleviated airway hyperresponsiveness, airway inflammation, and remodeling in a chronic asthma murine model, which indicated the TRPV1 receptor can be a potential drug target for chronic bronchial asthma (Choi et al., 2018). The gene discussed is TRPV1; the disease is chronic asthma.